Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.06 USD

160.06
2,502,191

+0.37 (0.23%)

Updated Oct 9, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Derek Lewis headshot

3 Dividend Kings Crushing the S&P 500 in 2022

Companies in the Dividend King club carry well-established and successful business operations, clearly displayed by their commendable commitment to shareholders over decades of increased dividend payouts.

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment

Sejuti Banerjea headshot

3 Stocks That Popped Yesterday

We're in the middle of earnings season, so it would be natural to assume that earnings reports are the biggest drivers of stocks during the season. But that isn't the case with a bunch that soared yesterday.

Pre-Markets in Green to Start a Fresh Month

Pre-Markets in Green to Start a Fresh Month

Mark Vickery headshot

Pre-Markets Up Ahead of New Fed Hike, Q3 Beats

Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).

AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View

AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.

Kinjel Shah headshot

Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod

Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.

The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Walmart, The Coca-Cola Company and NVIDIA

UnitedHealth Group, Johnson & Johnson, Walmart, The Coca-Cola Company and NVIDIA are part of the Zacks top Analyst Blog.

Shaun Pruitt headshot

Pfizer Earnings Preview: Growth & Diversification is Key

Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.

Sheraz Mian headshot

Top Analyst Reports for UnitedHealth, Johnson & Johnson, & Walmart

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Walmart Inc. (WMT).

Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?

AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals

J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

Sweta Killa headshot

JNJ Beats on Q3 Earnings: ETFs in Focus

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It outpaced revenue estimates and raised its full-year revenue guidance.

Stock Market News for Oct 19, 2022

U.S. stocks ended higher on Tuesday for the second straight day as another batch of solid earnings reports gave investors' confidence a boost.